about
Common genetic variants in candidate genes and risk of familial lymphoid malignanciesEndogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma.Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients.TRAIL in cancer therapy: present and future challenges.GRIM-19: A Double-edged Sword that Regulates Anti-Tumor and Innate Immune Responses.The impact of TNF superfamily molecules on overall survival in acute myeloid leukaemia: correlation with biological and clinical features.Targeting AML through DR4 with a novel variant of rhTRAILTargeted treatment for chronic lymphocytic leukemia.Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells.The role of TRAIL death receptors in the treatment of hematological malignancies.Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.Interferon-α in acute myeloid leukemia: an old drug revisited.Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches.Exploration of the lysis mechanisms of leukaemic blasts by chimaeric T-cells.Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.Differential effects of bexarotene on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines.Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2/Stat3.Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia.Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells.
P2860
Q24630753-795B086C-5521-4D39-B463-E7E35E6670C1Q33544118-ED3DED37-C237-4C20-A3D5-BD4B27B56CD4Q34122737-FEA84D27-0939-4F29-BB89-2851582E6878Q34291312-0B7477C5-8E7F-42CE-9AD5-3D88C4E63A15Q34497752-45D1BFC7-6FB1-4213-B0D0-1427E0D9A1DDQ34798476-A58AD02A-99E9-404D-970A-CB9F7530D330Q35377418-5387BDF5-F6E3-4060-8C04-B06FBA2935D8Q35599741-1E07F518-3028-46B3-806C-B2FB937B0A2AQ36461618-16EE0583-3AEE-4A79-900D-4AF11359F3A7Q37001645-734E7F04-2F3F-40BB-986E-A1C22FE3BE0DQ37059750-659B9CEF-D2CF-4398-88C1-E9CF900D09D3Q37821337-1B023C1C-2E68-47F0-A089-FE7404B7A8A5Q37832939-E68DA35B-9242-4DAD-B192-74ED2F178731Q37910914-980DF485-4E5E-4BB1-AD02-2D07BEF6FD10Q39682472-BD0796A1-9F76-482F-B50C-067F9DBE7016Q40094198-4B1622AB-BA0D-4AA0-A204-2FACBEB55C18Q40135330-712E4AB9-9550-4C87-81FB-825F35CE8FD5Q45947203-9C0D6D90-5A5C-45A4-A580-1BA9604F3884Q48592284-954B6D26-2FEE-49F3-8EFE-C6036985621FQ52583854-62E841E2-AC53-4736-95C8-A7F2F22081EE
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
On the TRAIL of a new therapy for leukemia.
@ast
On the TRAIL of a new therapy for leukemia.
@en
type
label
On the TRAIL of a new therapy for leukemia.
@ast
On the TRAIL of a new therapy for leukemia.
@en
prefLabel
On the TRAIL of a new therapy for leukemia.
@ast
On the TRAIL of a new therapy for leukemia.
@en
P2860
P356
P1433
P1476
On the TRAIL of a new therapy for leukemia
@en
P2093
Kaufmann SH
Steensma DP
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403946
P577
2005-12-01T00:00:00Z